3,560 material Form 8-K filings that 2,489 companies we cover made with the SEC in October 2026, each read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). 2,508 of them were written later, when past filings were added: a selection, not every 8-K of the month (see the note below).
Forestar Group's Executive Chairman, Donald J. Tomnitz, will retire effective October 31, 2026, and CEO Anthony W. Oxley will also serve as Executive Chairman from November 1, 2026. Tomnitz will provide advisory services through September 30, 2028 under a monthly fee of $41,667, and the filing also adds director Stacey H. Dwyer and notes that Samuel R. Fuller will not stand for re-election in 2027.
Donald J. Tomnitz retires as Executive Chairman effective October 31, 2026; he had served in the role since October 2017
Anthony W. Oxley, President and CEO, becomes Executive Chairman effective November 1, 2026, a role designated by D.R. Horton, Inc.
Tomnitz's advisory agreement runs through September 30, 2028 at $41,667 per month, with his RSUs and PSUs continuing to vest
Stacey H. Dwyer joins the Board effective November 1, 2026, and Samuel R. Fuller will not be nominated for re-election at the 2027 Annual Meeting
Gain Therapeutics appointed Jeanette Weidner as Vice President, Finance, effective October 28, 2026, and she will also serve as principal financial officer and principal accounting officer. The filing sets out her employment terms, including a $275,000 base salary, a target bonus of 35% of salary, and an option for 130,000 shares, which matter to shareholders because they define the compensation and severance commitments the company is taking on.
Appointment effective October 28, 2026; appointed on October 22, 2026
Annual base salary of $275,000 with an initial target bonus of 35% of base salary
Option to purchase up to 130,000 shares under the 2022 Equity Incentive Plan, vesting over four years
Severance of six months' base salary, or twelve months' base salary plus other benefits if terminated within twelve months after a change of control
Tronox Holdings plc's Board approved the appointment of Yasser Al-Daajani as a director effective October 27, 2026, nominated by Cristal International Holdings B.V. under a 2019 Shareholders Agreement. He is Executive Vice President, Petrochemicals at Tasnee, and will receive standard non-employee director pay. The filing reports no financial results, so the change is a board composition update rather than a change in company performance.
Board approved appointment on October 27, 2026; nominated by Cristal under the Shareholders Agreement dated April 10, 2019
Al-Daajani has served as Executive Vice President, Petrochemicals at Tasnee since June 2025
Annual cash retainer of $100,000, paid quarterly in arrears, plus restricted share units with a fair market value of $150,000 per year
Radian Group's Board appointed Daniel Kobell as Senior Executive Vice President and Chief Financial Officer on October 28, 2026. Mr. Kobell had served as Interim Chief Financial Officer since February 12, 2026, so the change makes his role permanent and gives the company a confirmed finance chief.
Appointment date: October 28, 2026, by the Board of Directors
Compass Minerals said its chief accounting officer, Ashley Ward, resigned effective October 23, 2026, and that the resignation was not due to any disagreement with the company. On October 28, 2026, the company appointed Brett Teuscher to the role under an offer letter with a $300,000 base salary and a 40% target bonus.
Ashley Ward resigned as chief accounting officer on October 22, 2026, effective October 23; the filing states no disagreement on operations, policies or practices.
Brett Teuscher, age 44, was named chief accounting officer on October 28, 2026; he joined the company in May 2026 as Senior Director, Internal Audit.
Teuscher's offer letter sets a $300,000 base salary, a bonus target of 40% of base salary, and a long-term incentive target of $115,000 per year.
Director Nathalie Bernier resigned from Bausch + Lomb's board and its Science and Technology Committee, effective at the close of business on October 28, 2026, and said the resignation was not due to any disagreement with the company. The board does not currently intend to fill the vacancy, and the company agreed to pay her prorated cash compensation and fully accelerate her unvested 2026 restricted share units under a general mutual release.
Nathalie Bernier resigned from the Board and Science and Technology Committee, effective October 28, 2026
Board does not currently intend to fill the vacancy
Company will pay prorated cash compensation and fully vest her outstanding 2026 restricted share units
Filing states the resignation was not due to any disagreement with the company
Azora Therapeutics, formerly Adial Pharmaceuticals, appointed Matthew Davidson, Ph.D. as President and Chief Executive Officer effective October 28, 2026, succeeding Cary J. Claiborne, whose employment was terminated. The board also appointed Celia Economides as Chief Financial Officer, succeeding Vinay Shah, and Julie Saiki, Ph.D. as Chief Strategy Officer. Stockholders approved increasing authorized common stock from 100,000,000 to 500,000,000 shares and the name change, with the new ticker AZR expected to begin trading October 29, 2026.
Matthew Davidson, Ph.D. appointed President and CEO effective October 28, 2026; Cary J. Claiborne's employment terminated, subject to a release for severance.
Celia Economides appointed CFO, succeeding Vinay Shah, whose employment was terminated effective October 28, 2026.
Authorized common stock increases from 100,000,000 to 500,000,000 shares; the amendment takes effect 12:01 AM Eastern on October 29, 2026.
Stockholders approved issuance of up to 23,561,896 shares on exercise of milestone pre-funded and incentive warrants, among other proposals.
Churchill Downs Incorporated appointed Michael Tucker as a Class II director on October 27, 2026, filling a seat created by a board size increase. The board now has eight members, and Tucker has not yet been named to any committees.
Michael Tucker appointed Class II director effective immediately, with term expiring at the 2028 Annual Meeting of Shareholders
Tucker is founder and managing partner of Orvieto Partners, L.P., and has more than 30 years of investment management experience
Board determined Tucker is independent under Nasdaq listing standards; compensation consistent with other non-employee directors
JAB Acquisition Corp I entered into a Consulting Services Agreement with its sponsor, JAB Acquisition Sponsor I, LLC, effective retrospectively from June 1, 2026. The company pays the sponsor $14,000 a month for Chairman Joshua Jagid to serve as CEO and Jack Bressman to serve as CFO, and the audit committee approved the related-party arrangement, including prior payments and a waiver of $50,000 in administrative fees.
Monthly consulting fee of $14,000: $8,000 to Joshua Jagid and $6,000 to Jack Bressman, paid from funds outside the trust account
$70,000 already paid covers June through October 2026
Sponsor waived $50,000 in administrative services fees for June through October 2026; payments resume at sponsor's discretion on November 10, 2026
Garrett Motion director Steven Tesoriere resigned from the board effective at the close of business on October 28, 2026, and the filing states the resignation was not due to any dispute with the company or the board. Tesoriere was an Oaktree-affiliated designee and had served on the Talent Management and Compensation Committee, so the change removes a board member tied to a major investor.
Steven Tesoriere resigned from the Board effective close of business October 28, 2026; resignation notice dated October 26, 2026
Tesoriere joined the Board in April 2021 as a designee of Oaktree-affiliated funds under the Series A Investor Rights Agreement
He had also served on the Talent Management and Compensation Committee and previously chaired the Finance Committee and Nominating and Governance Committee
The filing says the resignation was not the result of any dispute or disagreement with the company or the board
Effective October 29, 2026, Q2 Holdings named CFO Jonathan Price co-CEO alongside Matthew Flake, who remains president and chairman, and appointed Price to a board expanded from seven to eight members. Price will also keep the CFO role during the company's search for a new CFO, and his pay and severance terms were revised as part of the change.
Effective October 29, 2026, Price becomes co-CEO alongside Flake; the board increases from seven to eight members.
Price's annual base salary rises to $520,000, and he receives an RSU grant valued at $3 million vesting over four years.
Price remains chief financial officer during the search for a new CFO, with no date for that search given in the filing.
Severance is set at 200% of base salary plus a pro-rata bonus, or 250% as a lump sum if terminated within 60 days before to 24 months after a change in control.
Modular Medical director Duane DeSisto resigned from the board effective immediately on October 26, 2026, and the company said the resignation was not due to a disagreement over its operations, policies or practices. At the October 23, 2026 annual meeting, shareholders re-elected the board slate, approved a 2,500,000-share increase to the equity incentive plan, and ratified Farber Hass Hurley LLP as auditor for the fiscal year ending March 31, 2027.
Duane DeSisto resigned from the board on October 26, 2026, effective immediately, with no disagreement cited.
Approximately 65% of outstanding common shares were represented at the October 23, 2026 annual meeting.
Shareholders approved the equity incentive plan amendment, with 2,294,200 votes for and 811,943 against.
Shareholders ratified Farber Hass Hurley LLP with 6,171,976 votes for and 15,512 against.
ABM Industries disclosed that Executive Vice President and Chief Operating Officer Rene Jacobsen will voluntarily retire effective February 1, 2027. He will move to an Executive Advisor role from November 1, 2026 until his retirement date, so the operations chief role will change hands during that period.
Rene Jacobsen gave notice on October 28, 2026 of his voluntary retirement, effective February 1, 2027.
Jacobsen moves from Executive Vice President and Chief Operating Officer to Executive Advisor effective November 1, 2026.
The filing does not name a successor or state any financial figures related to the change.
Align Technology said Jennifer L. Davis, former CEO of Procter & Gamble's Global Healthcare business, will become President and CEO on December 31, 2026, replacing Joseph M. Hogan, who has led the company since 2015 and will retire from the role and become a strategic advisor. Davis joins the Board as a director on November 2, 2026, and the filing sets out her pay package, including a $1,300,000 base salary and a $2,000,000 signing bonus. The change marks a planned leadership transition at the company, and the filing discloses no changes to financial results or guidance.
Jennifer L. Davis joins as CEO-elect and director on November 2, 2026, and becomes President and CEO on December 31, 2026
Joseph M. Hogan, CEO since 2015, retires as CEO on December 31, 2026 and will serve as a strategic advisor under a one-year consulting agreement with a $150,000 annual fee
Davis's pay includes a $1,300,000 base salary, a 150% target bonus, equity awards of $9,900,000 and $6,600,000, and a $2,000,000 signing bonus
Board size increases from ten to eleven directors effective November 2, 2026
First Financial Bancorp's Board appointed Timothy A. Massa as a director effective October 27, 2026, and increased the Board from ten to eleven members. The filing says Massa retired from Kroger in September 2026 after serving as its executive vice president and chief associate experience officer for 12 years, and it describes his background in human capital leadership. The filing contains no financial results or guidance, so the change is a board composition update rather than a change in company performance.
Timothy A. Massa, 59, was appointed a director effective October 27, 2026, and the Board size rose from 10 to 11 directors.
Massa spent 16 years at Kroger, including 12 years on its senior leadership team, and retired on September 18, 2026.
His stock award was priced at $32.54, the October 27, 2026 closing price, and vests at the 2027 annual meeting.
Massa is expected to stand for election by shareholders at the 2027 annual meeting.
ManpowerGroup appointed Lidia Fonseca to its Board of Directors, effective November 1, 2026, increasing the board from twelve to thirteen directors. She previously served as Chief Digital and Technology Officer and Executive Vice President at Pfizer, and she has not been named to any board committee, so shareholders should note the appointment as a board composition change rather than an operating event.
Appointed October 26, 2026; service begins November 1, 2026; board size rises from twelve to thirteen.
Previously Chief Digital and Technology Officer and Executive Vice President at Pfizer, January 2019 to April 2026; currently Senior Advisor to Pfizer's CEO.
As a non-employee director, receives a $120,000 annual cash retainer and an annual deferred stock grant with a fair value of about $180,000, prorated for 2026.
Not appointed to any committee of the board; will enter the company's standard director indemnification agreement.
HomeTrust Bancshares (HTB) appointed Charles F. Bowman as a director of the company and of HomeTrust Bank, effective October 26, 2026. Bowman previously served as an advisory director since July 2026 and retired from Bank of America in 2022 after 26 years there, including as President of Bank of America for North Carolina. The filing says his board committee assignments have not yet been determined.
Appointed as director of HomeTrust Bancshares and HomeTrust Bank, effective October 26, 2026
Term expires in calendar year 2028
Compensation follows the same general arrangement as other non-employee directors, per the April 7, 2026 proxy statement
Board committee assignments have not yet been determined
Citizens & Northern Corporation said its board appointed director Aaron Singer as vice chair effective immediately, at an October 22, 2026 meeting. Chair Terry Lehman will step down at the 2027 annual shareholder meeting, when Singer is set to succeed him as chair, and Lehman intends to remain a director subject to nomination and election. The filing describes this as a planned leadership transition and does not include financial results or guidance.
Aaron Singer appointed Vice Chair of the Board effective immediately, per the October 22, 2026 board meeting
Terry Lehman to step down as Chair effective at the 2027 annual shareholder meeting; Singer to succeed him as Chair
Lehman intends to continue as a director, subject to Board nomination and shareholder election at the 2027 Annual Meeting
Singer has served on the Board since 2017 and chairs the Governance and Nominating Committee
Arcutis Biotherapeutics increased its board from ten to eleven directors and appointed Dr. Robert Scott, a former chief medical officer at AbbVie, effective October 23, 2026. The filing describes him as independent and he joins the Nominating and Corporate Governance Committee, and the company said the appointment was announced in a press release on October 28, 2026.
Dr. Robert Scott, age 73, appointed as a Class II director with a term expiring at the 2028 annual meeting
Initial stock option award for 20,507 shares; annual equity award fair valued at approximately $350,000
Annual cash retainer of $50,000 for board service and $5,000 for Nominating and Corporate Governance Committee service, prorated
T-Mobile US said Vice Chair G. Michael Sievert notified the Board on October 26, 2026, that he will resign from the Board and its Transaction Committee effective November 1, 2026, and will also stop serving as Vice Chair. The company said the timing matches the expiration of a September 19, 2025 amendment to his employment agreement, and that the resignation involves no disagreement over operations, policies or practices.
Resignation from the Board and Transaction Committee effective November 1, 2026
Notice to the Board given October 26, 2026
Timing tied to expiration of the September 19, 2025 amendment to his employment agreement
Company states the resignation is not due to any disagreement on operations, policies or practices
Vir Biotechnology's Board increased its size from eight to nine members and appointed Suzanne Topalian, M.D., to fill the new seat, effective October 27, 2026. She also joined the Science and Technology Committee and receives the standard non-employee director compensation, including automatic option and restricted stock unit grants.
Board expanded from eight to nine members; Dr. Topalian named Class III director through the 2028 annual meeting
Dr. Topalian appointed to the Science and Technology Committee, effective October 27, 2026
She received stock option and restricted stock unit awards under the 2019 Equity Incentive Plan on her appointment date
Company has signed its standard indemnity agreement with Dr. Topalian
AIB Data Centers appointed Jason Burnett as Chief Operations Officer, effective October 26, 2026, after the Board approved the appointment on October 23, 2026. He will oversee construction execution, procurement and data center operations, and he reports directly to CEO Jerry Tang. His pay includes a base salary that rises with site financings and bonuses tied to delivering data center sites to customers, so shareholders will see how these costs scale as projects advance.
Board appointed Jason K. Burnett as Chief Operations Officer on October 23, 2026, effective October 26, 2026; he previously served as Chief Operating Officer of Hivelocity from 2024 to 2026.
Base salary of $250,000, rising to $300,000 upon closing of financing for the CLT1 site and to $350,000 upon closing of financing for the next site.
Site delivery bonuses are paid in three stages (25%, 25% and 50%) for each site delivered to a customer, covering the first ten sites to reach customer handoff.
The Company also entered into indemnification agreements with all current directors and executive officers on October 26, 2026.
Gevo, Inc. said its Board approved the appointment of K’Lynne Johnson as a Class II director, effective November 4, 2026, with her term running to the 2027 annual meeting. The Board determined she is independent under Nasdaq listing standards, and the filing discloses her non-employee director pay, which does not change the company's financial results.
Annual cash retainer of $85,000 and an equity grant valued at $63,000 for non-employee director service
Appointment effective November 4, 2026; term expires at the 2027 annual meeting of stockholders
Board concluded Johnson is independent under Nasdaq listing standards
Johnson is former President and CEO of Elevance Renewable Sciences, Inc. and sits on the boards of FMC Corporation and Trinseo PLC
FuelCell Energy elected Peter Hopper, a digital infrastructure and investment executive, to its board effective October 26, 2026, after increasing the board to ten directors. He also joins the Compensation and Leadership Development Committee and the Nominating, Governance and Sustainability Committee, and the company says his data center and capital markets experience supports its power strategy for data centers.
Hopper receives an annual retainer of $75,000, prorated from October 26, 2026.
He is granted 2,231 restricted stock units that vest at the 2027 annual stockholder meeting.
Hopper is co-founder and managing director of Primary Digital Infrastructure and previously was a managing director at DigitalBridge.
The company announced the appointment in a press release dated October 28, 2026.
Enanta Pharmaceuticals said CEO Jay R. Luly, Ph.D., 70, will retire by February 1, 2027, after 23 years leading the company, and will serve as a strategic advisor for the rest of 2027. The board has started a search for a successor, considering both internal and external candidates, and named Tara L. Kieffer, Ph.D., to the newly created role of Chief Operating Officer. The filing does not include financial results, so the changes are mainly about management succession for shareholders.
Jay R. Luly, Ph.D., age 70, will retire as President and CEO by February 1, 2027, after 23 years with the company
Luly will continue as a strategic advisor for the remainder of 2027; the company expects to enter an agreement for this role
The board is searching for a successor, considering internal and external candidates
Tara L. Kieffer, Ph.D., age 48, was appointed Chief Operating Officer on October 28, 2026; she joined Enanta in 2020 as Chief Product Strategy Officer
Parsons Corporation (NYSE: PSN) said CFO Matt Ofilos will resign effective November 6, 2026, to pursue another professional opportunity, and that his resignation is not due to a disagreement with the company. The board appointed George Ball, a former CFO and current director, as interim CFO on the same date while it searches for a permanent successor.
Matt Ofilos resigns as CFO effective November 6, 2026; the filing says there was no disagreement on operations, policies or practices.
George Ball, CFO from 2008 to 2022 and a board member since 2022, was appointed interim CFO on October 26, 2026, effective November 6, 2026.
Ball will receive a $2.4 million restricted stock unit award that vests on the one-year anniversary, pro-rated for his actual interim service period.
The same-day third-quarter 2026 earnings release reaffirmed the fiscal 2026 revenue and adjusted EBITDA guidance midpoints and narrowed the ranges.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Briefs marked “Written later” were written in November 2026 for filings that were by then more than three weeks old, so months before mid-October 2026 hold a selection: every material 8-K of the past year for the 100 largest companies we cover and the last 15 important 8-Ks of every other one. Briefs the number check holds back are not shown or counted. Also: the last 45 days, briefs by company, A–Z and the live SEC filings wire.